Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Tuesday that it has been awarded a government contract valued at more than DKK700m to supply its MVA-BN smallpox/mpox vaccine to an undisclosed country during 2026 and 2027.

Deliveries are scheduled to begin in 2026, with the majority of revenue expected to be recognised in 2027.

The company said it has now secured approximately DKK2.2bn in Public Preparedness contracts for 2026, an increase of about DKK200m compared to the level previously announced.

Bavarian Nordic maintained its full-year 2026 guidance, forecasting Public Preparedness revenue of DKK2.3–2.5bn and total revenue of DKK5.5–5.7bn, with an EBITDA margin of approximately 28%.

The MVA-BN vaccine is the only non-replicating mpox vaccine approved in multiple markets, including the USA, EU/EEA, UK, Canada, Switzerland, Singapore, and Mexico.

The product was originally developed in collaboration with the US government as a smallpox vaccine suitable for immunocompromised individuals and is indicated for people at risk of smallpox or mpox infection.